Published in Transplantation on November 01, 2016
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol (2010) 9.72
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Siglecs and their roles in the immune system. Nat Rev Immunol (2007) 7.98
Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol (2013) 7.94
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 6.94
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med (2004) 6.48
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol (2007) 6.22
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40
Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med (2000) 5.34
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 4.99
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood (2006) 4.63
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
Immunosuppressive drugs for kidney transplantation. N Engl J Med (2004) 4.09
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity (2011) 3.76
Regulatory T cells: how do they suppress immune responses? Int Immunol (2009) 3.58
Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol (2010) 3.56
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40
The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev (2003) 3.40
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood (2006) 3.33
Rejection of the kidney allograft. N Engl J Med (2010) 3.30
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood (2007) 3.27
Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 3.27
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science (2003) 3.19
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med (2002) 3.17
Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol (2013) 2.96
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol (2009) 2.83
CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med (2002) 2.77
Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev (1999) 2.77
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
Development and maintenance of regulatory T cells. Immunity (2013) 2.61
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med (2000) 2.61
CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity (2003) 2.59
OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52
Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med (2007) 2.47
A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol (2006) 2.46
Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med (2005) 2.42
mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature (2013) 2.38
Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant (2010) 2.37
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med (2012) 2.14
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant (2012) 2.12
OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant (2015) 2.11
Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant (2010) 2.06
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03
A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol (2012) 1.96
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood (2008) 1.95
Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol (2004) 1.92
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant (2012) 1.79
Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol (2015) 1.78
Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med (2009) 1.76
Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation (2005) 1.75
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology (2009) 1.75
Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol (2008) 1.71
T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev (2011) 1.69
Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation (2001) 1.68
Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis. Cell Rep (2014) 1.66
Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest (2008) 1.66
Characterization of human type I and type II IMP dehydrogenases. J Biol Chem (1993) 1.65
TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci U S A (2008) 1.65
Development and use of alefacept to treat psoriasis. J Am Acad Dermatol (2003) 1.62
Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat Immunol (2015) 1.61
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol (2006) 1.60
B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. J Immunol (2011) 1.59
Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrol Dial Transplant (2011) 1.59
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 1.58
An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol (2010) 1.57
Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation. Transplantation (2010) 1.56
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant (2008) 1.55
Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol (2013) 1.55
Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant (2010) 1.54
The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant (2008) 1.52
Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation (2004) 1.52
Constitutive nuclear localization of NFAT in Foxp3+ regulatory T cells independent of calcineurin activity. J Immunol (2012) 1.51
Low vitamin D levels are associated with increased rejection and infections after lung transplantation. J Heart Lung Transplant (2012) 1.51
Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation (2009) 1.50
Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation (2012) 1.50
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. Am J Transplant (2013) 1.48
IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol (2010) 1.46
Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum (2012) 1.46